Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Tumor infiltrating lymphocyte therapy for renal cell carcinoma: methods for ex vivo expansion and T-cell memory induction

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Godwin, Andrew K; Fields, Timothy; Markiewicz, Mary A; DeKosky, Brandon; Behbod, Fariba; Vivian, Jay L
    • Publication Information:
      University of Kansas
    • Publication Date:
      2021
    • Collection:
      The University of Kansas: KU ScholarWorks
    • Abstract:
      Tumor infiltrating lymphocyte (TIL) therapy is a personalized treatment for locally advanced or metastatic cancer. TIL therapy requires the surgical excision of a portion of the malignant tissue and subsequent ex vivo expansion of tumor reactive immune cells, primarily T-lymphocytes (T-cells), prior to reinfusion into the patient. TIL therapy has been shown to be efficacious in numerous forms of cancer; however, a lack of consistent in vitro TIL production has hindered the development of this potentially curative cell therapy for renal cell carcinoma (RCC). I (Mitchell W. Braun) report my work, in the Godwin research laboratory, which has aimed to advance the prospect of TIL therapy for RCC. A novel method for TIL expansion has been developed that has shown a 94% success rate for creating TIL cultures from clear cell RCC. This method generates a TIL product with an optimal phenotype relative to other established TIL production protocols, namely the pre-rapid expansion protocol (PreREP)/REP and FTD + beads method. PreREP involves IL-2 supplementation alone as the source of exogenous stimulation during the first phase of expansion. The fresh tumor digests (FTD) + beads method involves supplementation of IL-2, as well as anti-CD3/CD28 beads to initiate TIL cultures. Relative to the PreREP and FTD + beads protocols, our method involves adherent cell depletion (ACD), referred to as panning, and generates significantly fewer regulatory (CD4+/CD25+/FOXP3+) (p=0.049, p=0.005), tissue-resident memory (CD8+/CD103+) (p=0.027, p=0.009), PD1+/TIM-3+ double-positive (p=0.009, p=0.011) and TIGIT+ T-cells (p=0.049, p=0.026), respectively. These phenotypic changes were achieved while increasing the average tumor reactive T-cell yield in the final TIL product. However, using this method a majority of the CD8+ expanded TILs bear an effector-memory or effector phenotype, which is sub-iv optimal for adoptive transfer and similar to the other protocols. Therefore, various methods to induce a less differentiated phenotype during in ...
    • File Description:
      123 pages; application/pdf
    • Relation:
      http://dissertations.umi.com/ku:17753; http://hdl.handle.net/1808/31766
    • Online Access:
      http://hdl.handle.net/1808/31766
      http://dissertations.umi.com/ku:17753
    • Rights:
      Copyright held by the author. ; openAccess
    • Accession Number:
      edsbas.9DE6E28B